Identification of unmeasured confounder effects and prevalence
We identified 4 studies reporting total exposure to MPA over dosing interval at steady-state [AUC0-12 (mg ×h/L) calculated based on dose-adjusted MPA concentrations] in renal transplant patients classified in respect to the SCLO1B3 c.334T>G SNP as combined TT/TG subjects vs. GG subjects: one French (Picard 2010 [1]) and one Dutch (Bouamar 2012 [2]) study, each reporting (separately) values in patients on IR MMF co-treated with either CsA or macrolactams (mostly tacrolimus, less commonly sirolimus); one Chinese study (Geng 2012 [3]) in which IR MMF was combined with CsA; and one Japanese study (Miura 2007 [4]) in which IR MMF was combined with tacrolimus. All values were crude, unadjusted mean±SD AUC0-12 quantified at different post-transplantation times (Figure S2).